Payment overview · 2025
General Payments
$2,290.41
129 reported records · 24 companies
Healthcare provider profile · identity verified
Jeffrey A Smith, MD
Allopathic & Osteopathic Physicians|Family Medicine · BISMARCK, ND · NPI 1629017785
Verified facts
What the public records show
CMS Open Payments records show Jeffrey A Smith, MD received $2,290.41 in general payments during 2025 across 129 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 19.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Kerendia, Mounjaro, Ozempic, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Kerendia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 342 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $439.62 | 19.2% | 19 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $242.29 | 10.6% | 18 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $204.48 | 8.9% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $184.03 | 8.0% | 15 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $164.32 | 7.2% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $145.28 | 6.3% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $126.68 | 5.5% | 8 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $124.11 | 5.4% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $89.45 | 3.9% | 4 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $89.00 | 3.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $65.52 | 2.9% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $56.34 | 2.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.63 | 2.2% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $50.67 | 2.2% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.60 | 1.7% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $33.87 | 1.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.72 | 1.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $32.23 | 1.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.36 | 0.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.27 | 0.9% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $20.23 | 0.9% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.00 | 0.9% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $19.90 | 0.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.81 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,201.41 | 128 |
| Education | $89.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $439.62 | 19 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $185.13 | 14 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $184.03 | 15 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $163.55 | 13 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $152.55 | 12 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $143.49 | 9 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $132.10 | 8 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $126.68 | 8 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $124.11 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $110.19 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $106.34 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $90.79 | 8 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $89.45 | 4 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $89.00 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $89.00 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $73.20 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $63.23 | 4 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $62.90 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $56.34 | 4 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $50.67 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $49.39 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $38.94 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $38.60 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $33.87 | 2 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $33.72 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $32.23 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.83 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $21.36 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 145 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 96 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
75 | 16 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
145 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
36 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
156 | 122 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
96 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
103 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
342 | 341 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
145 | 26 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 572 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 485 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 378 | 83 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 342 | 341 |
| Pantoprazole Sodium | Pantoprazole Sodium | 339 | 82 |
| Metformin Hcl | Metformin Hcl | 338 | 72 |
| Losartan Potassium | Losartan Potassium | 308 | 71 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 299 | 48 |
| Simvastatin | Simvastatin | 291 | 60 |
| Famotidine | Famotidine | 273 | 62 |
| Furosemide | Furosemide | 241 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 240 | 50 |
| Gabapentin | Gabapentin | 205 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 44 |
| Lisinopril | Lisinopril | 183 | 43 |
| Omeprazole | Omeprazole | 179 | 43 |
| Pregabalin | Pregabalin | 170 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 161 | 36 |
| Potassium Chloride | Potassium Chloride | 157 | 41 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 156 | 122 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 40 |
| Eliquis | Apixaban | 145 | 26 |
| Atorvastatin Calcium | Atorvastatin Calcium | 141 | 44 |
| Oxycodone Hcl | Oxycodone Hcl | 133 | 13 |
| Tramadol Hcl | Tramadol Hcl | 132 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 131 | 27 |
| Allopurinol | Allopurinol | 129 | 30 |
| Liothyronine Sodium | Liothyronine Sodium | 124 | 22 |
| Promethazine Hcl | Promethazine Hcl | 121 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 120 | 16 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 118 | 118 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 118 | 27 |
| Montelukast Sodium | Montelukast Sodium | 112 | 24 |
| Ezetimibe | Ezetimibe | 109 | 22 |
| Trulicity | Dulaglutide | 103 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 21 |
| Trazodone Hcl | Trazodone Hcl | 102 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 15 |
| Mounjaro | Tirzepatide | 96 | 13 |
| Alprazolam | Alprazolam | 94 | 19 |
| Sertraline Hcl | Sertraline Hcl | 94 | 24 |
| Repatha Sureclick | Evolocumab | 85 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 85 | 13 |
| Spironolactone | Spironolactone | 84 | 20 |
| Carvedilol | Carvedilol | 81 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 23 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 77 | 14 |
| Meloxicam | Meloxicam | 76 | 19 |
| Synthroid | Levothyroxine Sodium | 75 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 64 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 13 |
| Metformin Hcl Er | Metformin Hcl | 63 | 13 |
| Mirtazapine | Mirtazapine | 63 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 61 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 18 |
| Finasteride | Finasteride | 60 | 14 |
| Clonidine Hcl | Clonidine Hcl | 59 | 13 |
| Lorazepam | Lorazepam | 59 | 13 |
| Celecoxib | Celecoxib | 58 | 15 |
| Farxiga | Dapagliflozin Propanediol | 56 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 14 |
| Prednisone | Prednisone | 54 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 13 |
| Ozempic | Semaglutide | 53 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 52 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 13 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 45 | suppressed |
| Clonazepam | Clonazepam | 45 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 42 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 41 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | suppressed |
| Meperidine Hcl | Meperidine Hcl/Pf | 41 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl/Pf | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 37 | suppressed |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 36 | 36 |
| Diazepam | Diazepam | 35 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 35 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 33 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 26 |
| Methadone Hcl | Methadone Hcl | 31 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Carisoprodol | Carisoprodol | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Kerendia | Finerenone | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 13 |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 21 |
| Valacyclovir | Valacyclovir Hcl | 28 | 11 |
| Atenolol | Atenolol | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 23 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Armour Thyroid | Thyroid,pork | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 11 |
| Invokana | Canagliflozin | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 16 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 12 |
| Telmisartan | Telmisartan | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Codeine Sulfate | Codeine Sulfate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,290.41 · 129 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, GVOKE HYPOPEN, INGREZZA, JOURNAVX, Jornay PM, Kerendia, MOUNJARO, NUCALA, NURTEC ODT, OPSUMIT, OTEZLA, Ozempic, PROLIA, QULIPTA, Quviviq, REPATHA, REXULTI, Rybelsus, SAPIEN 3 Ultra RESILIA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, UPTRAVI, VOQUEZNA, VYEPTI, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error